Plain-English translation of NCT06948552 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called 5-ALA (Gleolan) — given by mouth before surgery — can help doctors see cancer cells in your upper urinary tract more clearly during an endoscopic procedure. The medication causes cancer tissue to fluoresce (glow) under special blue light, which may help your surgeon remove the tumor more completely. This is the first study looking at whether this approach works for this type of cancer.
Current surgical techniques sometimes miss small cancer cells that are hard to see with the naked eye. This medication has already been approved and used successfully in brain cancer surgery, and researchers want to know if the same glowing effect can help doctors find and remove upper urinary tract cancers more completely.
You likely qualify if…
You likely don't qualify if…
You will take a single oral dose of the medication 2 to 4 hours before your scheduled surgery. During your ureteroscopic procedure, your surgeon will use a special blue light endoscope to look for areas where the medication has caused cancer cells to glow. The doctors will measure how well the medication helps them see and remove the tumor, and they will monitor you for any side effects. The study involves about 10 participants total.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
United States